Novel quinoline-4-carboxamide derivatives potentiates apoptosis by targeting PDK1 to overcome chemo-resistance in colorectal cancer: Theoretical and experimental results

A series of novel N,2-diphenyl-6-(aryl/heteroaryl)quinoline-4-carboxamide derivatives were designed and synthesized using the Suzuki coupling reaction and evaluated them for their anticancer activity. These compounds were screened for anti-colon cancer activity through <i>in-silico</i> studies by molecular docking and molecular dynamics studies. Furthermore, the density functional theory was used to determine the molecule's electrical properties. The molecular electrostatic potential map is used to evaluate the charge distribution on the molecule surface. Unveiling that the compound <b>7a</b> (binding energy of -10.2 kcal/mol) has good inhibition activity compared to other synthesized compounds (<b>7b-7j</b>) as well as the standard drug Gefitinib. The stability of the compound <b>7a</b> with the 1OKY protein was confirmed through molecular dynamics simulation studies, indicating potential anti-colon cancer activity against <i>phosphoinositide dependent protein kinase-1</i> (PDK1). The <i>in-silico</i> ADMET pharmacokinetic properties indicate adherence to Lipinski's rule of five for favorable safety profiles and the compound falls within the optimal range for physicochemical and pharmacokinetic properties, which is comparable to that of the standard medication drug Gefitinib. The synthesized library of compounds was further evaluated for their <i>in-vitro</i> anticancer potency against colon, pancreatic and breast cancer cells. The results demonstrated that the compounds effectively suppressed the proliferative potential of the screened cells in a concentration-dependent manner, as revealed by MTT assay. The anticancer potential of these molecules was further evaluated by acridine orange/PI, and Hoechst/PI which demonstrates the potential of molecules to induce apoptosis in cancer cells. Further investigations and optimization of these derivatives could lead to the development of effective anticancer strategies.

Authors

Institutions

Publication Details

Journal
Heliyon
Published
2024-09-19
DOI
https://doi.org/10.1016/j.heliyon.2024.e38105
Citations
16
Primary Topic
Bioactive Compounds and Antitumor Agents
Type
article
Field-Weighted Citation Impact
5.61

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel quinoline-4-carboxamide derivatives potentiates apoptosis by targeting PDK1 to overcome chemo-resistance in colorectal cancer: Theoretical and experimental results

B.S. Chethan, Sudhanva M. Srinivasa, Veeresha Gowda Shalini, Darshini Gowda et al.
16 citations
Heliyon
Bioactive Compounds and Antitumor Agents
5.61
article

Novel quinoline-4-carboxamide derivatives potentiates apoptosis by targeting PDK1 to overcome chemo-resistance in colorectal cancer: Theoretical and experimental results

B.S. Chethan, Sudhanva M. Srinivasa, Veeresha Gowda Shalini, Darshini Gowda, Kanchugarakoppal Subbegowda Rangappa, A Priyadarshini, Vinay Kumar D C, Shobith Rangappa, H B
article en
16 citations

Abstract

A series of novel N,2-diphenyl-6-(aryl/heteroaryl)quinoline-4-carboxamide derivatives were designed and synthesized using the Suzuki coupling reaction and evaluated them for their anticancer activity. These compounds were screened for anti-colon cancer activity through <i>in-silico</i> studies by molecular docking and molecular dynamics studies. Furthermore, the density functional theory was used to determine the molecule's electrical properties. The molecular electrostatic potential map is used to evaluate the charge distribution on the molecule surface. Unveiling that the compound <b>7a</b> (binding energy of -10.2 kcal/mol) has good inhibition activity compared to other synthesized compounds (<b>7b-7j</b>) as well as the standard drug Gefitinib. The stability of the compound <b>7a</b> with the 1OKY protein was confirmed through molecular dynamics simulation studies, indicating potential anti-colon cancer activity against <i>phosphoinositide dependent protein kinase-1</i> (PDK1). The <i>in-silico</i> ADMET pharmacokinetic properties indicate adherence to Lipinski's rule of five for favorable safety profiles and the compound falls within the optimal range for physicochemical and pharmacokinetic properties, which is comparable to that of the standard medication drug Gefitinib. The synthesized library of compounds was further evaluated for their <i>in-vitro</i> anticancer potency against colon, pancreatic and breast cancer cells. The results demonstrated that the compounds effectively suppressed the proliferative potential of the screened cells in a concentration-dependent manner, as revealed by MTT assay. The anticancer potential of these molecules was further evaluated by acridine orange/PI, and Hoechst/PI which demonstrates the potential of molecules to induce apoptosis in cancer cells. Further investigations and optimization of these derivatives could lead to the development of effective anticancer strategies.

HeliyonVol. 10(19)
University of Mysore (IN), JSS Science and Technology University (IN), Institute for Molecular Medicine (US), Indian Institute of Management Bangalore (IN)
Indian Institute of Science, Council of Scientific and Industrial Research, India, University of Mysore
Good health and well-being
Openalex Percentile: Top 3%
Bioactive Compounds and Antitumor Agents
5.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.